Rifampicin increases the extent of P2Y12 receptor blockade achieved by clopidogrel administration

被引：0
|
作者：
Patil, S. B. G. [1 ]
Judge, H. M. [1 ]
Buckland, R. J. [1 ]
Jakubowski, J. A. [2 ]
Storey, R. F. [1 ]
机构：
[1] Univ Sheffield, Cardiovasc Res Unit, Sheffield, S Yorkshire, England
[2] Lilly Res Labs, Res, Indianapolis, IN USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OC-MO-012
引用
收藏
页码：105 / 105
页数：1
相关论文
共 50 条
  • [31] Blockade of the P2Y12 signaling Pathway with Clopidogrel Restrains Treg Proliferation In Vivo during Sepsis and in Vitro
    Vemulapalli, Harika
    Samara, Albayati
    Tsygankov, Alexander Y.
    Liverani, Elisabetta
    BLOOD, 2018, 132
  • [32] Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12
    Braun, Oscar Oe
    Amisten, Stefan
    Wihlborg, Anna-Karin
    Hunting, Karen
    Nilsson, David
    Erlinge, David
    PURINERGIC SIGNALLING, 2007, 3 (03) : 195 - 201
  • [33] Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y1 and the P2Y12 receptor and is correlated with protein expression of P2Y12
    Oscar Ö Braun
    Stefan Amisten
    Anna-Karin Wihlborg
    Karen Hunting
    David Nilsson
    David Erlinge
    Purinergic Signalling, 2007, 3 : 195 - 201
  • [34] EXPERIMENTALLY-INDUCED CARDIAC ISCHEMIA IN PIGS INCREASES PLATELET REACTIVITY AND REDUCES THE EFFECT OF P2Y12 RECEPTOR BLOCKADE
    Moscardo, A.
    Hernandiz, A.
    Cortina, B.
    Cerrada, I.
    Latorre, A.
    Teresa Santos, M.
    Valles, J.
    THROMBOSIS RESEARCH, 2014, 133 : S100 - S100
  • [35] P2Y12 Receptors In Ischemic Inflammation: A New Role For Clopidogrel?
    Webster, Carla
    McManus, April
    Hokari, Masaaki
    Tang, Xian Nan
    Yenari, Midori A.
    STROKE, 2011, 42 (03) : E296 - E296
  • [36] The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration
    Jakubowski, Joseph A.
    Payne, Christopher D.
    Li, Ying G.
    Brandt, John T.
    Small, David S.
    Farid, Nagy A.
    Salazar, Daniel E.
    Winters, Kenneth J.
    THROMBOSIS AND HAEMOSTASIS, 2008, 99 (02) : 409 - 415
  • [37] Antiplatelet Therapy n ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors
    Ristorto, Jessica
    Messas, Nathan
    Marchandot, Benjamin
    Kibler, Marion
    Hess, Sebastien
    Meyer, Nicolas
    Schaeffer, Michael
    Tuzin, Nicolas
    Ohlmann, Patrick
    Jesel, Laurence
    Morel, Olivier
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (08) : 674 - 689
  • [38] P2Y12 inhibition by clopidogrel increases adverse clinical events after transcatheter aortic valve replacement
    Matsushita, Kensuke
    Marchandot, Benjamin
    Kibler, Marion
    Heger, Joe
    Peillex, Marilou
    Trimaille, Antonin
    Hess, Sebastien
    Grunebaum, Lelia
    Ohana, Mickael
    Reydel, Antje
    Jesel, Laurence
    Ohlmann, Patrick
    Morel, Olivier
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 360 : 53 - 61
  • [39] The antiplatelet effect of ASP1645, a novel P2Y12 receptor antagonist, compared with clopidogrel
    Uemura, T.
    Kawasaki, T.
    Sakata, C.
    Shigenaga, T.
    Moritani, Y.
    Takasaki, J.
    Koga, Y.
    Ito, H.
    Mutoh, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 946 - 946
  • [40] Reversible binding of cangrelor to the P2Y12 receptor prevents the binding of clopidogrel and prasugrel active metabolites
    Buckland, R. J.
    Judge, H. M.
    Sugidachi, A.
    Jakubowski, J. A.
    Storey, R. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 942 - 942
12345